Gong_2016_Oncotarget_7_68688

Reference

Title : Constructing Bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression - Gong_2016_Oncotarget_7_68688
Author(s) : Gong Y , Wang L , Chippada-Venkata U , Dai X , Oh WK , Zhu J
Ref : Oncotarget , 7 :68688 , 2016
Abstract :

To understand the heterogeneity of prostate cancer (PCa) and identify novel underlying drivers, we constructed integrative molecular Bayesian networks (IMBNs) for PCa by integrating gene expression and copy number alteration data from published datasets. After demonstrating such IMBNs with superior network accuracy, we identified multiple sub-networks within IMBNs related to biochemical recurrence (BCR) of PCa and inferred the corresponding key drivers. The key drivers regulated a set of common effectors including genes preferentially expressed in neuronal cells. NLGN4Y-a protein involved in synaptic adhesion in neurons-was ranked as the top gene closely linked to key drivers of myogenesis subnetworks. Lower expression of NLGN4Y was associated with higher grade PCa and an increased risk of BCR. We show that restoration of the protein expression of NLGN4Y in PC-3 cells leads to decreased cell proliferation, migration and inflammatory cytokine expression. Our results suggest that NLGN4Y is an important negative regulator in prostate cancer progression. More importantly, it highlights the value of IMBNs in generating biologically and clinically relevant hypotheses about prostate cancer that can be validated by independent studies.

PubMedSearch : Gong_2016_Oncotarget_7_68688
PubMedID: 27626693
Gene_locus related to this paper: human-NLGN4Y

Related information

Gene_locus human-NLGN4Y

Citations formats

Gong Y, Wang L, Chippada-Venkata U, Dai X, Oh WK, Zhu J (2016)
Constructing Bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression
Oncotarget 7 :68688

Gong Y, Wang L, Chippada-Venkata U, Dai X, Oh WK, Zhu J (2016)
Oncotarget 7 :68688